BLPH Bellerophon Therapeutics, Inc.

1.26
0  -2%
Previous Close 1.29
Open 1.29
Price To book 2.27
Market Cap 40.37M
Shares 32,039,000
Volume 191,651
Short Ratio 1.32
Av. Daily Volume 1,580,230

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated May 2016. Data due mid-2017.
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 3 commenced enrollment June 2016. Interim analysis due 4Q 2017 with top-line data due mid-2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2 initiated 3Q 2016. Data due mid-2017.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)

Latest News

  1. Bellerophon Slumps on Underwhelming INOpulse Data
  2. Clinical Data on INOpulse® Presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT)
  3. Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation
  4. The Difference Between Spectacular News and No News
  5. Bellerophon Therapeutics posts 4Q loss
  6. Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
  7. LifeSci Capital Initiates Coverage of Bellerophon Therapeutics
  8. These 5 Stocks Under $10 Could Make You a Lot of Money
  9. INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Bellerophon Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm
  10. Robbins Arroyo LLP is Investigating the Officers and Directors of Bellerophon Therapeutics, Inc. (BLPH) on Behalf of Shareholders
  11. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellerophon Therapeutics, Inc. (BLPH)
  12. Second Law Firm Hits Bellerophon (BLPH)
  13. INVESTOR ALERT: Investigation of Bellerophon Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
  14. Law Firm Targets Bellerophon Therapeutics (BLPH)
  15. Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital Corp.